A fifth person has been cured of HIV following a stem cell transplant for cancer; a new study examining a treatment of spinal cord stimulation after stroke had favorable results; some food companies enraged by proposed FDA healthy food guidelines.
HIV Cured in Fifth Person After Stem Cell Transplant
German researchers say a man has been cured of HIV, the fifth known person to be cured, after a stem cell transplant was carried out following several rounds of chemotherapy, reported The Hill. The study was published in Nature and described the case of a 53-year-old patient who was diagnosed with HIV and then diagnosed with acute myeloid leukemia a few years later. The cancer treatment consisted of a matched stem cell transplant with someone believed to have a mutation resistant to HIV infection.
Preliminary Spinal Cord Stimulation Study Helps Patients After Stroke
A small study with 2 patients showed evidence that spinal cord stimulation focused on arm and hand weakness and paralysis can reverse the effects of a stroke, according to The New York Times. The study, published in Nature Medicine, is preliminary, and it isn’t known how long the effects will last for once the electrodes are removed. In the study, patients received a treatment 5 days a week for 4 weeks. The patients retained some of the improvement once the electrodes were removed.
Proposed Healthy Food FDA Guidelines Met With Massive Backlash from Manufacturers
Following new proposed guidelines on what can be called healthy by the FDA, various major food manufacturers have responded with backlash, even citing concerns of First Amendment right infringement on using the word “healthy,” STAT reported. The proposed guidelines were presented in September 2022 and said that for foods to be marketed as healthy, they would need to include specific amounts of nutritious ingredients such as fruits and vegetables and small amounts of added sugar, sodium, and saturated fat. The proposal was supported by some major health organizations like the American Society for Nutrition and the Robert Wood Johnson Foundation.
Progression-Free Survival in Relapsed Multiple Myeloma Extended With Ixazomib, Data Show
November 26th 2024Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to chimeric antigen receptor T cells and bispecific antibodies.
Read More
Real-World Data Confirm Ibrutinib's Role in Relapsed CLL
November 26th 2024This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Unfavorable Health-Related Social Needs Associated With Lower Cardiovascular Health Scores
November 25th 2024Adults with more unfavorable health-related social needs, such as unemployment or food insecurity, had a higher prevalence of low cardiovascular health, highlighting the importance of addressing social determinants to improve population health.
Read More